November 17, 2026

Your BMI may be telling you only half the story, and a massive new study of more than 844,000 adults says doctors should stop treating it as the final word on obesity.

The research, published Wednesday, Nov. 11, in the journal Nature, put a new way of diagnosing obesity to its biggest real-world test yet. Instead of relying on BMI alone, the approach adds a simple tape-measure check of your waist and then asks one key question: is extra body fat already harming how your organs or body work?

The answer, it turns out, makes a huge difference. People whose excess fat was already causing health problems had a much higher risk of dying than people who simply carried extra weight. And BMI by itself got a meaningful number of people wrong in both directions.

Here is what the study found, what it means for you, and what it does not prove.

BMI vs. obesity: what the new study actually tested

For decades, the standard rule has been simple: a BMI of 30 or higher means obesity. But BMI is just weight divided by height squared. It cannot tell muscle from fat, and it says nothing about where fat is stored or whether it is causing harm.

In January 2025, a commission of 56 experts convened by The Lancet Diabetes & Endocrinology and chaired by Dr. Francesco Rubino of King’s College London proposed a two-step alternative:

  1. Step 1: Confirm excess body fat. Use BMI plus at least one body measurement, such as waist circumference, waist-to-hip ratio or waist-to-height ratio.
  2. Step 2: Check for harm. Look at medical history for signs that the extra fat is impairing organ function or daily activities. The commission listed 18 obesity-related conditions and signs of dysfunction; examples cited in coverage include cardiovascular disease, joint pain and sleep apnea.

That second step splits obesity into two categories:

  • Clinical obesity: excess fat is already impairing how organs or the body work. In this framework, it is treated as an active disease.
  • Preclinical obesity: excess fat raises future health risks, but organ and whole-body function are still intact.

The new Nature paper, titled “Validation of clinical and preclinical obesity across global cohorts,” is the largest test so far of whether this framework holds up with real patients. It was led by King’s College London with first author An Pan of Huazhong University of Science and Technology in China. Collaborators included Pennington Biomedical Research Center in Louisiana and the University of Colorado Anschutz Medical Campus.

Who was in the study

The team analyzed health records from 844,108 adults ages 18 to 74 across four countries, according to a summary of the paper by News-Medical. None had a history of stroke, heart attack or cancer at the start.

Cohort Country Participants
UK Biobank United Kingdom 436,203
All of Us Research Program United States 218,841
Kailuan Study China 137,795
SIDIAP primary care database Spain 51,269

The U.S. data came from the NIH’s All of Us program, the same giant research effort behind recent findings on how your DNA shapes your response to common drugs.

Key findings: BMI got it wrong both ways

1. BMI missed some people and mislabeled others

Across the four groups, BMI alone missed obesity-level body fat in up to 8.6% of participants and wrongly labeled up to 3.1% as having obesity, according to the King’s College London news release. Adding waist measurements raised the share of people identified with obesity by about 3.3 to 7.4 percentage points, depending on the population.

2. In the U.S., nearly half of adults met the new obesity criteria

Among the American participants, obesity prevalence under the combined BMI-plus-waist criteria was 48.1%, a 5.6-point jump over BMI alone, per the News-Medical summary. That compared with 27.3% in the UK, 26.1% in Spain and 21.3% in China.

But only a slice of that group had clinical obesity. Clinical obesity made up roughly 23% to 31% of all obesity cases across the cohorts, and its population prevalence ranged from 5.6% to 10.9%. The U.S. sat at the top of that range, at 10.9%.

3. Clinical obesity carried a much higher death risk

This is the headline result. Compared with people who did not have obesity or organ dysfunction, those with clinical obesity had about a 69% higher risk of death from any cause, as reported by both Live Science and News-Medical. Preclinical obesity carried a more modest increase, about 19%, according to News-Medical’s summary.

Just as striking: overweight or obesity defined by BMI alone, without the waist-based confirmation, was not linked to higher mortality in the analysis. In other words, the extra measurements helped separate people at real risk from people BMI flagged for no clear reason.

One important note: the U.S. cohort had too little follow-up time to be included in the death analyses, so the mortality numbers come from the UK, Spain and China.

4. Most people with preclinical obesity did not get sicker

Over 10 years, 77% to 91% of people with preclinical obesity did not progress to clinical obesity, depending on the cohort. In the U.S. group, with shorter follow-up, the estimated four-year rate of developing clinical obesity was 8.5%.

“Preclinical obesity should therefore be neither treated automatically as active disease nor dismissed as harmless.”
Francesco Rubino, senior author, King’s College London

Why this matters for obesity care in the US

The framework could change who gets treated, and how. Rubino argued that care should be “matched to their needs: no less, and no more,” as quoted by Euronews.

Dr. Robert Eckel of CU Anschutz, one of the study’s U.S.-based researchers, put the key takeaway plainly in the university’s release: “we need to distinguish between having excess body fat and having an active disease.”

That distinction has real-world stakes in the age of GLP-1 drugs like Wegovy and Zepbound. Live Science noted that a 2025 analysis found some patients who qualify for obesity medications under current FDA guidelines might be reclassified as preclinical under the new system and could lose access to prescriptions. On the flip side, people with a “normal” BMI but risky belly fat could be newly identified.

Dr. Jennifer Hwang of the University of Chicago, who was not part of the Nature study, told Live Science: “we are definitely missing some people who actually need obesity treatment but just did not meet the BMI criteria.” Her own earlier analysis of U.S. national survey data, presented at the ObesityWeek conference in 2025 and reported by Healio, estimated that about 61% of U.S. adults would have obesity under the Lancet criteria in 2021–2023, compared with 43% by BMI alone. That was a conference presentation, not a peer-reviewed paper, so treat the figure as preliminary.

Study limitations: what this research doesn’t prove

This is a big, well-designed study, but it has real limits, many acknowledged by the authors themselves:

  • It looked backward. The analysis was retrospective and relied on existing health records, not new patients followed under a controlled plan.
  • Records varied. How organ dysfunction was measured, and how often, differed across the four cohorts.
  • Cause is hard to pin down. The authors note limited ability to say whether a given person’s organ problems were actually caused by obesity.
  • Associations, not proof. The findings show the framework predicts risk better than BMI; they do not show that using it leads to better health outcomes.
  • No U.S. death data. The American cohort’s follow-up was too short for the mortality analysis.
  • Thresholds still debated. Waist cutoffs vary by ethnicity, and the summary notes a universal waist-to-height cutoff of 0.50 flagged many people who showed no added death risk. Outside experts say more consensus is needed on what counts as clinical obesity.

The authors call for prospective studies using clinically validated diagnoses across diverse populations before the framework is widely adopted.

Practical takeaways: what to do with this news

You do not need to panic about your BMI, or ignore it either. Here are sensible, source-backed steps:

  • Treat BMI as a starting point. CU Anschutz researchers describe BMI as a starting point, not a complete diagnosis.
  • Ask about your waist. At your next checkup, ask whether your clinician measures waist circumference or waist-to-height ratio, especially if your BMI is near a cutoff.
  • Look at the whole picture. Blood pressure, blood sugar, cholesterol, joint pain and sleep problems are the kinds of signs this framework weighs. Routine screening matters; see our guide to diabetes screening and early action.
  • If you are told you have “preclinical” obesity, that is a prompt for prevention, not a reason to ignore it. Most people in this category did not progress over a decade, but their risk was still modestly higher.
  • On a GLP-1 or considering one? Do not change or stop medication based on headlines. Talk through how any new criteria might affect your treatment plan.
  • Healthy habits still count. For more on what research says helps people stay healthier longer, read what really slows aging, according to Yale researchers.

This article is for information only. Talk to your doctor before making changes to your diet, exercise or medications.

FAQ: BMI and obesity under the new definition

Is BMI being replaced?

Not officially. The Lancet Commission’s framework keeps BMI as a first screening step but adds waist measurements and a check for organ dysfunction. The new Nature study supports the framework, but U.S. guidelines and FDA drug-eligibility rules have not changed based on it.

What is the difference between clinical and preclinical obesity?

Clinical obesity means excess body fat is already impairing organ function or daily activities. Preclinical obesity means excess fat raises future health risks, but your body is still functioning normally. In the study, clinical obesity carried a far higher death risk.

Could I be told I have obesity even with a “normal” BMI?

Yes. In this study, BMI alone missed obesity-level body fat in up to 8.6% of participants, often because fat stored around the waist does not show up in a weight-and-height calculation.

Sources

Bookmark USA One News for the latest health studies, explained in plain English, every week.

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Copy link
Powered by Social Snap